All Publications

Data provided by UCSF Profiles, powered by CTSI at UCSF
  1. Duan M, Nguyen DC, Joyner CJ, Saney CL, Tipton CM, Andrews J, Lonial S, Kim C, Hentenaar I, Kosters A, Ghosn E, Jackson A, Knechtle S, Maruthamuthu S, Chandran S, Martin T, Rajalingam R, Vincenti F, Breeden C, Sanz I, Gibson G, Eun-Hyung Lee F. Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell Analyses. bioRxiv. 2023 Jan 20. View in PubMed
  2. Looney CM, Schroeder A, Tavares E, Garg J, Schindler T, Vincenti F, Redfield RR, Jordan SC, Busque S, Woodle ES, Khan J, Eastham J, Micallef S, Austin CD, Morimoto A. Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients. Transplant Direct. 2023 Feb; 9(2):e1436. View in PubMed
  3. Raval AD, Kistler KD, Tang Y, Vincenti F. Burden of neutropenia and leukopenia among adult kidney transplant recipients: A systematic literature review of observational studies. Transpl Infect Dis. 2022 Dec 12; e14000. View in PubMed
  4. Hricik D, Armstrong B, Alhamad T, Brennan D, Bromberg J, Bunnapradist S, Chandran S, Fairchild R, Foley D, Formica R, Gibson I, Kesler K, Kim SJ, Mannon R, Menon M, Newell K, Nickerson P, Odim J, Poggio E, Sung R, Shapiro R, Tinckam K, Vincenti F, Heeger P. Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients. J Am Soc Nephrol. 2022 Oct 04. View in PubMed
  5. Brar S, Berry R, Raval AD, Tang Y, Vincenti F, Skartsis N. Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia. Clin Transplant. 2022 04; 36(4):e14583. View in PubMed
  6. Skartsis N, Peng Y, Ferreira LMR, Nguyen V, Ronin E, Muller YD, Vincenti F, Tang Q. IL-6 and TNFα Drive Extensive Proliferation of Human Tregs Without Compromising Their Lineage Stability or Function. Front Immunol. 2021; 12:783282. View in PubMed
  7. Budde K, Prashar R, Haller H, Rial MC, Kamar N, Agarwal A, de Fijter JW, Rostaing L, Berger SP, Djamali A, Leca N, Allamassey L, Gao S, Polinsky M, Vincenti F. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. J Am Soc Nephrol. 2021 12 01; 32(12):3252-3264. View in PubMed
  8. Aubert O, Divard G, Pascual J, Oppenheimer F, Sommerer C, Citterio F, Tedesco H, Chadban S, Henry M, Vincenti F, Srinivas T, Watarai Y, Legendre C, Bernhardt P, Loupy A. Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. BMJ Open. 2021 10 07; 11(10):e052138. View in PubMed
  9. Lee LM, Zhang H, Lee K, Liang H, Merleev A, Vincenti F, Maverakis E, Thomson AW, Tang Q. A Comparison of Ex Vivo Expanded Human Regulatory T Cells Using Allogeneic Stimulated B Cells or Monocyte-Derived Dendritic Cells. Front Immunol. 2021; 12:679675. View in PubMed
  10. Danovitch GM, Bunnapradist S, Cohen D, Hariharan S, McKay D, Ratner L, Stegall MD, Steiner RW, Stock PG, Vincenti F. Tests for the noninvasive diagnosis of kidney transplant rejection should be evaluated by kidney transplant programs. Am J Transplant. 2021 11; 21(11):3811. View in PubMed
  11. Zarinsefat A, Hartoularos G, Rychkov D, Rashmi P, Chandran S, Vincenti F, Yee CJ, Sarwal MM. Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation. Front Genet. 2020; 11:610682. View in PubMed
  12. Chandran S, Leung J, Hu C, Laszik ZG, Tang Q, Vincenti FG. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial. Am J Transplant. 2021 07; 21(7):2543-2554. View in PubMed
  13. Vincenti F, Kim J, Gouveia D, Pelle G, Mayne TJ, Neylan JF. Phase 3 trial Design of the Hepatocyte Growth Factor Mimetic ANG-3777 in Renal Transplant Recipients With Delayed Graft Function. Kidney Int Rep. 2021 Feb; 6(2):296-303. View in PubMed
  14. Kirk AD, Adams AB, Durrbach A, Ford ML, Hildeman DA, Larsen CP, Vincenti F, Wojciechowski D, Woodle ES. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients. Am J Transplant. 2021 05; 21(5):1691-1698. View in PubMed
  15. Dobi D, Vincenti F, Chandran S, Greenland JR, Bowman C, Chen A, Junger H, Laszik ZG. The impact of belatacept on the phenotypic heterogeneity of renal T cell-mediated alloimmune response: The critical role of maintenance treatment and inflammatory load. Clin Transplant. 2020 11; 34(11):e14084. View in PubMed
  16. Zarinsefat A, Hartoularos G, Chandran S, Yee CJ, Vincenti F, Sarwal MM. Single-cell RNA sequencing of Tocilizumab-treated peripheral blood mononuclear cells as an in vitro model of inflammation. bioRxiv. 2020 Oct 06. View in PubMed
  17. Yang JYC, Sarwal RD, Sigdel TK, Damm I, Rosenbaum B, Liberto JM, Chan-On C, Arreola-Guerra JM, Alberu J, Vincenti F, Sarwal MM. A urine score for noninvasive accurate diagnosis and prediction of kidney transplant rejection. Sci Transl Med. 2020 03 18; 12(535). View in PubMed
  18. Sigdel T, Nguyen M, Liberto J, Dobi D, Junger H, Vincenti F, Laszik Z, Sarwal MM. Assessment of 19 Genes and Validation of CRM Gene Panel for Quantitative Transcriptional Analysis of Molecular Rejection and Inflammation in Archival Kidney Transplant Biopsies. Front Med (Lausanne). 2019; 6:213. View in PubMed
  19. Harel E, Shoji J, Abraham V, Miller L, Laszik ZG, King A, Dobi D, Szabo G, Hann B, Sarwal MM, Craik CS, Vincenti F. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes. Transplantation. 2020 01; 104(1):54-60. View in PubMed
  20. Vincenti F, Klintmalm G, Yang H, Ram Peddi V, Blahunka P, Conkle A, Santos V, Holman J. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation. Am J Transplant. 2020 01; 20(1):172-180. View in PubMed
  21. Pascual J, Berger SP, Chadban SJ, Citterio F, Kamar N, Hesselink DA, Legendre C, Eisenberger U, Oppenheimer F, Russ GR, Sommerer C, Rigotti P, Srinivas TR, Watarai Y, Henry ML, Vincenti F, Tedesco-Silva H. Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. Transplant Rev (Orlando). 2019 10; 33(4):191-199. View in PubMed
  22. Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA, Formica R, Schindler T, Tran H, Looney C, Jamois C, Green C, Morimoto A, Rajwanshi R, Schroeder A, Cascino MD, Brunetta P, Borie D. Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. Am J Transplant. 2019 11; 19(11):3035-3045. View in PubMed
  23. Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J, TRANSFORM investigators. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant. 2019 11; 19(11):3018-3034. View in PubMed
  24. Pineda S, Sigdel TK, Liberto JM, Vincenti F, Sirota M, Sarwal MM. Characterizing pre-transplant and post-transplant kidney rejection risk by B cell immune repertoire sequencing. Nat Commun. 2019 04 23; 10(1):1906. View in PubMed
  25. Harel E, Shoji J, Abraham V, Miller L, Laszik Z, Thurison T, King A, Olshen A, Leung J, Szabo G, Hann B, H?yer-Hansen G, Craik CS, Vincenti F. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation. Clin Transplant. 2019 03; 33(3):e13487. View in PubMed
  26. Busque S, Vincenti FG, Tedesco Silva H, O'Connell PJ, Yoshida A, Friedewald JJ, Steinberg SM, Budde K, Broeders EN, Kim YS, Hahn CM, Li H, Chan G. Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial. Transplant Direct. 2018 Sep; 4(9):e380. View in PubMed
  27. Webber AB, Tatapudi V, Maw TT, Peralta C, Leung JCY, Vincenti F. Nuclear Factor of Activated T Cell-regulated Cytokine Gene Expression for Adjustment of Tacrolimus in Kidney Transplant Recipients: A Randomized Controlled Pilot Trial. Transplant Direct. 2018 Jul; 4(7):e369. View in PubMed
  28. Vincenti F, Budde K, Merville P, Shihab F, Ram Peddi V, Shah M, Wyburn K, Cassuto-Viguier E, Weidemann A, Lee M, Flegel T, Erdman J, Wang X, Lademacher C. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. Am J Transplant. 2018 12; 18(12):2945-2954. View in PubMed
  29. Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F, TRANSFORM Investigators. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol. 2018 07; 29(7):1979-1991. View in PubMed
  30. Florman S, Vincenti F, Durrbach A, Abouljoud M, Bresnahan B, Garcia VD, Mulloy L, Rice K, Rostaing L, Zayas C, Calderon K, Meier-Kriesche U, Polinsky M, Yang L, Medina Pestana J, Larsen CP. Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT. Clin Transplant. 2018 04; 32(4):e13225. View in PubMed
  31. Sigdel TK, Nguyen M, Dobi D, Hsieh SC, Liberto JM, Vincenti F, Sarwal MM, Laszik Z. Targeted Transcriptional Profiling of Kidney Transplant Biopsies. Kidney Int Rep. 2018 May; 3(3):722-731. View in PubMed
  32. Wojciechowski D, Chandran S, Webber A, Hirose R, Vincenti F. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients. Transplant Proc. 2017 Oct; 49(8):1773-1778. View in PubMed
  33. Vincenti F, Blancho G, Durrbach A, Grannas G, Griny? J, Meier-Kriesche HU, Polinsky M, Yang L, Larsen CP. Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly. Am J Transplant. 2017 Dec; 17(12):3219-3227. View in PubMed
  34. Chandran S, Tang Q, Sarwal M, Laszik ZG, Putnam AL, Lee K, Leung J, Nguyen V, Sigdel T, Tavares EC, Yang JYC, Hellerstein M, Fitch M, Bluestone JA, Vincenti F. Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants. Am J Transplant. 2017 Nov; 17(11):2945-2954. View in PubMed
  35. Wojciechowski D, Chandran S, Yang JYC, Sarwal MM, Vincenti F. Retrospective evaluation of the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: A single-center clinical experience. Clin Transplant. 2017 Sep; 31(9). View in PubMed
  36. Tang Q, Vincenti F. Transplant trials with Tregs: perils and promises. J Clin Invest. 2017 Jun 30; 127(7):2505-2512. View in PubMed
  37. Asare A, Kanaparthi S, Lim N, Phippard D, Vincenti F, Friedewald J, Pavlakis M, Poggio E, Heeger P, Mannon R, Burrell BE, Morrison Y, Bridges N, Sanz I, Chandraker A, Newell KA, Turka LA. B Cell Receptor Genes Associated With Tolerance Identify a Cohort of Immunosuppressed Patients With Improved Renal Allograft Graft Function. Am J Transplant. 2017 Oct; 17(10):2627-2639. View in PubMed
  38. Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J, Focal Segmental Glomerulosclerosis Study Group. A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis. Kidney Int Rep. 2017 Sep; 2(5):800-810. View in PubMed
  39. Vincenti F. Belatacept: the challenges with transformational drugs. Transl Androl Urol. 2017 Apr; 6(2):341-342. View in PubMed
  40. Wojciechowski D, Chandran S, Vincenti F. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients. Clin Transplant. 2017 05; 31(5). View in PubMed
  41. Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. Am J Kidney Dis. 2017 May; 69(5):587-594. View in PubMed
  42. Wojciechowski D, Vincenti F. Current status of costimulatory blockade in renal transplantation. Curr Opin Nephrol Hypertens. 2016 11; 25(6):583-590. View in PubMed
  43. Wojciechowski D, Vincenti F. Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2. Adv Chronic Kidney Dis. 2016 09; 23(5):306-311. View in PubMed
  44. Klintmalm GB, Vincenti F, Kirk A. Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials. Am J Transplant. 2016 Nov; 16(11):3077-3078. View in PubMed
  45. Vincenti F. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016 06 30; 374(26):2600-1. View in PubMed
  46. Webber AB, Vincenti F. An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed. Transplantation. 2016 Apr; 100(4):836-43. View in PubMed
  47. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016 Jan 28; 374(4):333-43. View in PubMed
  48. Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H, Yue S, Vincenti F. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation. 2016 Jan; 100(1):184-93. View in PubMed
  49. Sigdel TK, Bestard O, Tran TQ, Hsieh SC, Roedder S, Damm I, Vincenti F, Sarwal MM. A Computational Gene Expression Score for Predicting Immune Injury in Renal Allografts. PLoS One. 2015; 10(9):e0138133. View in PubMed
  50. Vincenti F, Silva HT, Busque S, O'Connell PJ, Russ G, Budde K, Yoshida A, Tortorici MA, Lamba M, Lawendy N, Wang W, Chan G. Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients. Am J Transplant. 2015 Jun; 15(6):1644-53. View in PubMed
  51. Roedder S, Sigdel T, Salomonis N, Hsieh S, Dai H, Bestard O, Metes D, Zeevi A, Zeevi A, Gritsch A, Cheeseman J, Macedo C, Peddy R, Medeiros M, Vincenti F, Asher N, Salvatierra O, Shapiro R, Kirk A, Reed EF, Reed E, Sarwal MM. The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med. 2014 Nov; 11(11):e1001759. View in PubMed
  52. Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, D'Addio F, Chin M, Tezza S, Ben Nasr M, Mattinzoli D, Ikehata M, Corradi D, Schumacher V, Buvall L, Yu CC, Chang JM, La Rosa S, Finzi G, Solini A, Vincenti F, Rastaldi MP, Reiser J, Krolewski AS, Mundel PH, Sayegh MH. Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol. 2014 Jul; 25(7):1415-29. View in PubMed
  53. Chandran S, Vincenti F. Clinical aspects: focusing on key unique organ-specific issues of renal transplantation. Cold Spring Harb Perspect Med. 2014 Feb 01; 4(2). View in PubMed
  54. Rostaing L, Vincenti F, Griny? J, Rice KM, Bresnahan B, Steinberg S, Gang S, Gaite LE, Moal MC, Mondrag?n-Ramirez GA, Kothari J, Pupim L, Larsen CP. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 2013 Nov; 13(11):2875-83. View in PubMed
  55. Wojciechowski D, Vincenti F. Tofacitinib in kidney transplantation. Expert Opin Investig Drugs. 2013 Sep; 22(9):1193-9. View in PubMed
  56. van Gelder T, Baan C, Vincenti F, Mannon RB. Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma. Transpl Int. 2013 Sep; 26(9):938-48. View in PubMed
  57. Vagefi PA, Qian JJ, Carlson DM, Aparici CM, Hirose R, Vincenti F, Wojciechowski D. Native renal function after combined liver-kidney transplant for type 1 hepatorenal syndrome: initial report on the use of postoperative Technetium-99 m-mercaptoacetyltriglycine scans. Transpl Int. 2013 May; 26(5):471-6. View in PubMed
  58. Wojciechowski D, Chanda R, Chandran S, Lee B, Webber A, Macaraig M, Tomlanovich S, Vincenti F. Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation. 2012 Dec 15; 94(11):1117-23. View in PubMed
  59. Wojciechowski D, Vincenti F. Belatacept in kidney transplantation. Curr Opin Organ Transplant. 2012 Dec; 17(6):640-7. View in PubMed
  60. Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, Scheuermann EH, Klinger M, Russ G, Pescovitz MD, Prestele H. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant. 2013 Jan; 13(1):136-45. View in PubMed
  61. Wojciechowski D, Vincenti F. Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update. Biologics. 2012; 6:385-93. View in PubMed
  62. Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int. 2012 Dec; 25(12):1257-67. View in PubMed
  63. Grinyo J, Alberu J, Contieri FL, Manfro RC, Mondragon G, Nainan G, Rial Mdel C, Steinberg S, Vincenti F, Dong Y, Thomas D, Kamar N. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transpl Int. 2012 Oct; 25(10):1059-64. View in PubMed
  64. Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S, Weimar W, Kim YS, Lawendy N, Lan SP, Kudlacz E, Krishnaswami S, Chan G. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012 Sep; 12(9):2446-56. View in PubMed
  65. Vincenti F. Are calcineurin inhibitors-free regimens ready for prime time? Kidney Int. 2012 Nov; 82(10):1054-60. View in PubMed
  66. Vincenti F. Beyond belatacept: praise and progress for the FDA. Am J Transplant. 2012 Mar; 12(3):513-4. View in PubMed
  67. Wojciechowski D, Vincenti F. Targeting JAK3 in kidney transplantation: current status and future options. Curr Opin Organ Transplant. 2011 Dec; 16(6):614-9. View in PubMed
  68. Jen KY, Nguyen TB, Vincenti FG, Laszik ZG. C4d/CD34 double-immunofluorescence staining of renal allograft biopsies for assessing peritubular capillary C4d positivity. Mod Pathol. 2012 Mar; 25(3):434-8. View in PubMed
  69. Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012 Jan; 12(1):210-7. View in PubMed
  70. Rostaing L, Neumayer HH, Reyes-Acevedo R, Bresnahan B, Florman S, Vitko S, Heifets M, Xing J, Thomas D, Vincenti F. Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes. Clin J Am Soc Nephrol. 2011 Nov; 6(11):2696-704. View in PubMed
  71. Vincenti F, Dritselis A, Kirkpatrick P. Belatacept. Nat Rev Drug Discov. 2011 Aug 31; 10(9):655-6. View in PubMed
  72. Wojciechowski D, Vincenti F. Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation. Semin Immunol. 2011 Jun; 23(3):157-64. View in PubMed
  73. Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation. 2011 May 27; 91(10):1057-64. View in PubMed
  74. Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Griny? J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011 May 15; 91(9):976-83. View in PubMed
  75. Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, Nicholson M, Wahlberg J, Wissing KM, Abrams K, Witte S, Woodle ES. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant. 2011 Jul; 11(7):1444-55. View in PubMed
  76. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F. A phase 1, single-dose study of fresolimumab, an anti-TGF-� antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 2011 Jun; 79(11):1236-43. View in PubMed
  77. Humar A, IMPACT Investigators Steering Committee, Peeters P, Abramowicz D, Humar A, Lebranchu Y, Hauser I, Jardine A, Limaye AP, Vincenti F, Punch JD, Blumberg E. Response to questions regarding the design and results of the IMPACT trial. Am J Transplant. 2011 Jan; 11(1):177-8. View in PubMed
  78. Griny? J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010 Dec 27; 90(12):1521-7. View in PubMed
  79. Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010 Dec 27; 90(12):1427-31. View in PubMed
  80. Larsen CP, Griny? J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010 Dec 27; 90(12):1528-35. View in PubMed
  81. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010 Dec 27; 90(12):1595-601. View in PubMed
  82. Wojciechowski D, Vincenti F. How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept. Curr Opin Organ Transplant. 2010 Dec; 15(6):697-702. View in PubMed
  83. Ferguson R, Griny? J, Vincenti F, Kaufman DB, Woodle ES, Marder BA, Citterio F, Marks WH, Agarwal M, Wu D, Dong Y, Garg P. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011 Jan; 11(1):66-76. View in PubMed
  84. Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, Steinberg S, Vincenti F, Shi R, Di Russo G, Thomas D, Griny? J. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011 Feb; 6(2):430-9. View in PubMed
  85. Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis. 2010 Dec; 56(6):1127-39. View in PubMed
  86. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010 Aug; 10(8):1870-80. View in PubMed
  87. Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, Klempnauer J, Lang P, Larsen CP, Mühlbacher F, Nashan B, Soulillou JP, Vanrenterghem Y, Wekerle T, Agarwal M, Gujrathi S, Shen J, Shi R, Townsend R, Charpentier B. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010 Sep; 21(9):1587-96. View in PubMed
  88. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010 May; 10(5):1228-37. View in PubMed
  89. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G, Xing J, Garg P, Griny? J. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010 Mar; 10(3):547-57. View in PubMed
  90. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010 Mar; 10(3):535-46. View in PubMed
  91. Wojciechowski D, Hirose R, Stock P, Vincenti F, Baxter-Lowe LA, Salvatierra O. Kidney transplantation at UCSF: 8,300 transplants and onward. Clin Transpl. 2010; 161-7. View in PubMed
  92. Vincenti F, Cohen SD, Appel G. Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases. Clin J Am Soc Nephrol. 2010 Jan; 5(1):142-51. View in PubMed
  93. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, Green MD, Jha V, Josephson MA, Kiberd BA, Kreis HA, McDonald RA, Newmann JM, Obrador GT, Vincenti FG, Cheung M, Earley A, Raman G, Abariga S, Wagner M, Balk EM, Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010 Feb; 77(4):299-311. View in PubMed
  94. Busque S, Leventhal J, Brennan DC, Steinberg S, Klintmalm G, Shah T, Mulgaonkar S, Bromberg JS, Vincenti F, Hariharan S, Slakey D, Peddi VR, Fisher RA, Lawendy N, Wang C, Chan G. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant. 2009 Aug; 9(8):1936-45. View in PubMed
  95. Yabu JM, Vincenti F. Kidney transplantation: the ideal immunosuppression regimen. Adv Chronic Kidney Dis. 2009 Jul; 16(4):226-33. View in PubMed
  96. Bunnapradist S, Vincenti F. Transplantation: To convert or not to convert: lessons from the CONVERT trial. Nat Rev Nephrol. 2009 Jul; 5(7):371-3. View in PubMed
  97. Murphy B, Vincenti F, Meier-Kriesche HU. The AST's perspective on the proposed kidney allocation system. Am J Transplant. 2009 Jul; 9(7):1500. View in PubMed
  98. Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H, Daloze P. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. Transplantation. 2009 May 15; 87(9):1360-6. View in PubMed
  99. Tavakol MM, Vincenti FG, Assadi H, Frederick MJ, Tomlanovich SJ, Roberts JP, Posselt AM. Long-term renal function and cardiovascular disease risk in obese kidney donors. Clin J Am Soc Nephrol. 2009 Jul; 4(7):1230-8. View in PubMed
  100. Arias M, Campistol JM, Vincenti F. Evolving trends in induction therapy. Transplant Rev (Orlando). 2009 Apr; 23(2):94-102. View in PubMed
  101. Latek R, Fleener C, Lamian V, Kulbokas E, Davis PM, Suchard SJ, Curran M, Vincenti F, Townsend R. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation. 2009 Mar 27; 87(6):926-33. View in PubMed
  102. Kuypers DR, Ekberg H, Grinyó J, Nashan B, Vincenti F, Snell P, Mamelok RD, Bouw RM. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. Clin Pharmacokinet. 2009; 48(5):329-41. View in PubMed
  103. Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008 Oct; 8(10):2086-96. View in PubMed
  104. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant. 2008 Oct; 8(10):1972-81. View in PubMed
  105. Halloran PF, Bromberg J, Kaplan B, Vincenti F. Tolerance versus immunosuppression: a perspective. Am J Transplant. 2008 Jul; 8(7):1365-6. View in PubMed
  106. Grinyó J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, Rashford M, Nasmyth-Miller C, Voulgari A, Spleiss O, Truman M, Essioux L. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int. 2008 Sep; 21(9):879-91. View in PubMed
  107. Vincenti F, Klintmalm G, Halloran PF. Open letter to the FDA: new drug trials must be relevant. Am J Transplant. 2008 Apr; 8(4):733-4. View in PubMed
  108. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J, FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008 Feb; 8(2):307-16. View in PubMed
  109. Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol. 2008 Feb; 121(2):299-306; quiz 307-8. View in PubMed
  110. Candiano G, Musante L, Petretto A, Bruschi M, Santucci L, Urbani A, Scolari F, Gusmano R, Carraro M, Zennaro C, Vincenti F, Ghiggeri GM. Proteomics of plasma and urine in primary nephrotic syndrome in children. Contrib Nephrol. 2008; 160:17-28. View in PubMed
  111. Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant. 2008 Jan; 8(1):222-7. View in PubMed
  112. Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, Laskow D, Slakey DP, Lorber MI, Garg JP, Garovoy M. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007 Jul; 7(7):1770-7. View in PubMed
  113. Yabu JM, Vincenti F. Novel immunosuppression: small molecules and biologics. Semin Nephrol. 2007 Jul; 27(4):479-86. View in PubMed
  114. Pescovitz MD, Vincenti F, Hart M, Melton L, Whelchel J, Mulgaonkar S, McKay D, Leung M, Calleja E, Bouw MR. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol. 2007 Dec; 64(6):758-71. View in PubMed
  115. Vincenti F. Costimulation blockade--what will the future bring? Nephrol Dial Transplant. 2007 May; 22(5):1293-6. View in PubMed
  116. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N, DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Inves. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007 Jun; 7(6):1506-14. View in PubMed
  117. Tomlanovich SJ, Vincenti F. Sirolimus: defining nephrotoxicity in the renal transplant recipient. Clin J Am Soc Nephrol. 2007 Mar; 2(2):198-9. View in PubMed
  118. Musante L, Candiano G, Petretto A, Bruschi M, Dimasi N, Caridi G, Pavone B, Del Boccio P, Galliano M, Urbani A, Scolari F, Vincenti F, Ghiggeri GM. Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albumin. J Am Soc Nephrol. 2007 Mar; 18(3):799-810. View in PubMed
  119. Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007 Mar; 7(3):560-70. View in PubMed
  120. Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med. 2007; 58:347-58. View in PubMed
  121. Arns W, Cibrik DM, Walker RG, Mourad G, Budde K, Mueller EA, Vincenti F. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation. 2006 Oct 27; 82(8):1004-12. View in PubMed
  122. Brennan TV, Fuller TF, Vincenti F, Chan S, Chang CK, Bostrom A, Zlatunich JK, Tomlanovich SJ, Feng S. Living donor kidney transplant recipients and clinical trials: participation profiles and impact on post-transplant care. Am J Transplant. 2006 Oct; 6(10):2429-35. View in PubMed
  123. Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal. Semin Liver Dis. 2006 Aug; 26(3):201-10. View in PubMed
  124. Vincenti F, de Andrés A, Becker T, Choukroun G, Cole E, González-Posada JM, Kumar MA, Moore R, Nadalin S, Nashan B, Rostaing L, Saito K, Yoshimura N. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl Int. 2006 Jun; 19(6):446-57. View in PubMed
  125. Vincenti F. Antibodies come back to the forefront in transplantation. Clin J Am Soc Nephrol. 2006 May; 1(3):399. View in PubMed
  126. Vincenti F, Mendez R, Curtis J, Light J, Pearson T, Wu YM, Katz SM, Akalin E, Esterl R, Gugliuzza K, Shihab F, Jordan S, Jonsson J, Molmenti E, Barbeito R. A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients. Transplantation. 2005 Oct 15; 80(7):910-6. View in PubMed
  127. Land W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation. 2005 Oct 15; 80(2 Suppl):S221-34. View in PubMed
  128. Vincenti F. Current use and future trends in induction therapy. Saudi J Kidney Dis Transpl. 2005 Oct-Dec; 16(4):506-13. View in PubMed
  129. Aziz S, Callen PW, Vincenti F, Hirose R. Rapidly developing nephrocalcinosis in a patient with end-stage liver disease who received a domino liver transplant from a patient with known congenital oxalosis. J Ultrasound Med. 2005 Oct; 24(10):1449-52. View in PubMed
  130. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B, Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005 Aug 25; 353(8):770-81. View in PubMed
  131. Vincenti F. A drug of the past, a lesson for the future. Pediatr Transplant. 2005 Jun; 9(3):267-8. View in PubMed
  132. Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa JV, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005 Jun; 19(3):291-8. View in PubMed
  133. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant. 2005 Jun; 5(6):1179-85. View in PubMed
  134. Vincenti F, Tuncer M, Castagneto M, Klinger M, Friman S, Scheuermann EH, Wiecek A, Russ GR, Martinek A, Nonnast-Daniel B, DIRECT Study Group. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation. Transplant Proc. 2005 Mar; 37(2):1001-4. View in PubMed
  135. Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlethwaite JR, Vincenti F, Cohen DJ. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant. 2005 Feb; 19(1):130-6. View in PubMed
  136. Vincenti F, Rostaing L, DIRECT (Diabetes Incidence after REnal Transplantation: Neoral C2 monitoring versus Tacrolimus) inve. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation. Contemp Clin Trials. 2005 Feb; 26(1):17-24. View in PubMed
  137. Woodle ES, Vincenti F, Lorber MI, Gritsch HA, Hricik D, Washburn K, Matas AJ, Gallichio M, Neylan J. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant. 2005 Jan; 5(1):157-66. View in PubMed
  138. Vincenti F. Chronic induction. What's new in the pipeline. Contrib Nephrol. 2005; 146:22-29. View in PubMed
  139. Lipshutz GS, Flechner SM, Govani MV, Vincenti F. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant. 2004 Dec; 4(12):2132-4. View in PubMed
  140. Vincenti F. Interleukin-2 receptor antagonists and aggressive steroid minimization strategies for kidney transplant patients. Transpl Int. 2004 Sep; 17(8):395-401. View in PubMed
  141. Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004 Sep-Oct; 8(5):231-3. View in PubMed
  142. Vincenti F. A decade of progress in kidney transplantation. Transplantation. 2004 May 15; 77(9 Suppl):S52-61. View in PubMed
  143. Ghiggeri GM, Carraro M, Vincenti F. Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant. 2004 May; 19(5):1036-40. View in PubMed
  144. Vincenti F, Brennan TV, Fuller TF, Feng S. Optimizing the use of cyclosporine (Neoral) for recipients of living donor kidneys. Transplant Proc. 2004 Mar; 36(2 Suppl):50S-53S. View in PubMed
  145. Ramos E, Vincenti F, Lu WX, Shapiro R, Trofe J, Stratta RJ, Jonsson J, Randhawa PS, Drachenberg CB, Papadimitriou JC, Weir MR, Wali RK. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation. 2004 Jan 15; 77(1):131-3. View in PubMed
  146. Pescovitz MD, Bumgardner G, Gaston RS, Kirkman RL, Light S, Patel IH, Nieforth K, Vincenti F. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clin Transplant. 2003 Dec; 17(6):511-7. View in PubMed
  147. Posselt AM, Vincenti F, Bedolli M, Lantz M, Roberts JP, Hirose R. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. Transplantation. 2003 Jul 15; 76(1):190-5. View in PubMed
  148. Vincenti F. Immunosuppression minimization: current and future trends in transplant immunosuppression. J Am Soc Nephrol. 2003 Jul; 14(7):1940-8. View in PubMed
  149. Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, Eklund B, Kliem V, Legendre C, Morais Sarmento AL, Vincenti F. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant. 2003 Jul; 3(7):835-45. View in PubMed
  150. Vincenti F, Stock P. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco. Transplant Proc. 2003 May; 35(3 Suppl):183S-186S. View in PubMed
  151. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant. 2003 Mar; 3(3):306-11. View in PubMed
  152. Vincenti F. New monoclonal antibodies in renal transplantation. Minerva Urol Nefrol. 2003 Mar; 55(1):57-66. View in PubMed
  153. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant. 2003 Jan; 3(1):50-2. View in PubMed
  154. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant. 2002 Nov; 2(10):898-903. View in PubMed
  155. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002 Mar 15; 73(5):775-82. View in PubMed
  156. Parasrampuria DA, Lantz MV, Birnbaum JL, Vincenti FG, Benet LZ. Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. J Clin Pharmacol. 2002 Mar; 42(3):304-11. View in PubMed
  157. Vincenti F. Interleukin-2 receptor monoclonal antibodies in renal transplantation: current use and emerging regimens. Transplant Proc. 2001 Nov-Dec; 33(7-8):3169-71. View in PubMed
  158. Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F, Phase III Daclizumab Study Group. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation. 2001 Sep 15; 72(5):839-45. View in PubMed
  159. Bumgardner GL, Ramos E, Lin A, Vincenti F, Daclizumab Triple Therapy and Double Therapy Groups. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation. 2001 Aug 27; 72(4):642-7. View in PubMed
  160. Vincenti F. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen. Transplant Proc. 2001 Jun; 33(4 Suppl):11S-18S. View in PubMed
  161. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001 May 15; 71(9):1282-7. View in PubMed
  162. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Neylan J, Roza A, Somberg K. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation. Transplant Proc. 2001 Feb-Mar; 33(1-2):1011-2. View in PubMed
  163. Vincenti F. Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial. Transplant Proc. 2001 Feb-Mar; 33(1-2):1019-20. View in PubMed
  164. Vincenti F. The role of newer monoclonal antibodies in renal transplantation. Transplant Proc. 2001 Feb-Mar; 33(1-2):1000-1. View in PubMed
  165. Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI, Maia M, Light SE. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation. 2000 Dec 27; 70(12):1707-12. View in PubMed
  166. Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL, Stock PG, Hirose R. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant. 2000 Dec; 14(6):550-4. View in PubMed
  167. Pirsch J, Bekersky I, Vincenti F, Boswell G, Woodle ES, Alak A, Kruelle M, Fass N, Facklam D, Mekki Q. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol. 2000 May; 40(5):527-32. View in PubMed
  168. Korsun A, Vincenti F, Ruck D, Whitelaw N, Ladoulis C, Whitelaw G. The role of daclizumab in balancing resources for inpatient and outpatient transplant services. Prog Transplant. 2000 Mar; 10(1):21-4. View in PubMed
  169. Ekberg H, Bäckman L, Tufveson G, Tydén G, Nashan B, Vincenti F. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl Int. 2000; 13(2):151-9. View in PubMed
  170. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz CJ, Roza AM, Vincenti F, George V. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation. 1999 Sep 15; 68(5):635-41. View in PubMed
  171. Vincenti F. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation. Transplant Proc. 1999 Sep; 31(6):2206-7. View in PubMed
  172. Vincenti F. Potential of daclizumab in solid organ transplantation. BioDrugs. 1999 May; 11(5):333-41. View in PubMed
  173. Vincenti F, Grinyo J, Ramos E, Nashan B, Stuart F, Kuypers D, Brattstrom C, Cho S, Ekberg H, Johnson R. Can antibody prophylaxis allow sparing of other immunosuppressives? Transplant Proc. 1999 Feb-Mar; 31(1-2):1246-8. View in PubMed
  174. Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, Ouseph R, Peddi VR, Pelz C, Roza AM, Vincenti F, George V. Recurrent and de novo glomerular disease after renal transplantation: a report from renal allograft disease registry. Transplant Proc. 1999 Feb-Mar; 31(1-2):223-4. View in PubMed
  175. Hirose R, Vincenti F. Review of transplantation--1999. Clin Transpl. 1999; 295-315. View in PubMed
  176. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation. 1998 Dec 27; 66(12):1736-40. View in PubMed
  177. Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc. 1998 Aug; 30(5):2155-8. View in PubMed
  178. Bumgardner GL, Amend WC, Ascher NL, Vincenti FG. Single-center long-term results of renal transplantation for IgA nephropathy. Transplantation. 1998 Apr 27; 65(8):1053-60. View in PubMed
  179. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998 Jan 15; 338(3):161-5. View in PubMed
  180. Bretan PN, Freise C, Goldstein R, Osorio R, Tomlanovich S, Amend W, Mathur V, Vincenti F. Selection strategies for successful utilization of less than 15.kg pediatric donor kidneys. Transplant Proc. 1997 Dec; 29(8):3274-5. View in PubMed
  181. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation. 1997 Apr 15; 63(7):977-83. View in PubMed
  182. Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group. Transplant Proc. 1997 Feb-Mar; 29(1-2):304-5. View in PubMed
  183. Bretan PN, Friese C, Goldstein RB, Osorio RW, Tomlanovich S, Amend W, Mathur V, Vincenti F. Immunologic and patient selection strategies for successful utilization of less than 15 kg pediatric donor kidneys--long term experiences with 40 transplants. Transplantation. 1997 Jan 27; 63(2):233-7. View in PubMed
  184. Vincenti F, Lantz M, Birnbaum J, Garovoy M, Mould D, Hakimi J, Nieforth K, Light S. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation. 1997 Jan 15; 63(1):33-8. View in PubMed
  185. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation. 1996 Oct 15; 62(7):900-5. View in PubMed
  186. Woodle ES, Thistlethwaite JR, Gordon JH, Laskow D, Deierhoi MH, Burdick J, Pirsch JD, Sollinger H, Vincenti F, Burrows L, Schwartz B, Danovitch GM, Wilkinson AH, Shaffer D, Simpson MA, Freeman RB, Rohrer RJ, Mendez R, Aswad S, Munn SR, Wiesner RH, Delmonico FL, Neylan J, Whelchel J. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation. 1996 Sep 15; 62(5):594-9. View in PubMed
  187. Vincenti F, Laskow DA, Neylan JF, Mendez R, Matas AJ. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. Transplantation. 1996 Jun 15; 61(11):1576-81. View in PubMed
  188. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996 Apr 04; 334(14):878-83. View in PubMed
  189. Stock PG, Lantz M, Light S, Vincenti F. In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients. Transplant Proc. 1996 Apr; 28(2):915-6. View in PubMed
  190. Vincenti F, Danovitch GM, Neylan JF, Steiner RW, Everson MP, Gaston RS. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study. Transplantation. 1996 Feb 27; 61(4):573-7. View in PubMed
  191. Lam PW, Wachs ME, Somberg KA, Vincenti F, Lake JR, Ferrell LD. Fibrosing cholestatic hepatitis in renal transplant recipients. Transplantation. 1996 Feb 15; 61(3):378-81. View in PubMed
  192. Sorof JM, Vartanian RK, Olson JL, Tomlanovich SJ, Vincenti FG, Amend WJ. Histopathological concordance of paired renal allograft biopsy cores. Effect on the diagnosis and management of acute rejection. Transplantation. 1995 Dec 15; 60(11):1215-9. View in PubMed
  193. Orloff SL, Stempel CA, Wright TL, Tomlanovich SJ, Amend WJ, Stock PG, Melzer JS, Vincenti F. Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. Clin Transplant. 1995 Apr; 9(2):119-24. View in PubMed
  194. Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A. Phase II FK 506 multicenter concentration control study: one-year follow-up. Transplant Proc. 1995 Feb; 27(1):809-11. View in PubMed
  195. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer JS, Roberts JP, Tomlanovich SJ, Vincenti F. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation. 1995 Jan 27; 59(2):230-4. View in PubMed
  196. Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis. 1994 Apr; 23(4):574-81. View in PubMed
  197. Vincenti FG, Vasconcelos M, Birnbaum JL, Tomlanovich SJ, Amend WJ, Melzer JS, Snyder JP. Pentoxifylline reduces the first-dose reactions following OKT3. Transplant Proc. 1993 Apr; 25(2 Suppl 1):57-9. View in PubMed
  198. Vincenti F, Lake J, Wright T, Kuo G, Weber P, Stempel C. Nontransmission of hepatitis C from cadaver kidney donors to transplant recipients. Transplantation. 1993 Mar; 55(3):674-5. View in PubMed
  199. Stempel CA, Lake J, Kuo G, Vincenti F. Hepatitis C--its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation. 1993 Feb; 55(2):273-6. View in PubMed
  200. Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F. Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med. 1992 Apr; 92(4):375-83. View in PubMed
  201. Krams SM, Falco DA, Villanueva JC, Rabkin J, Tomlanovich SJ, Vincenti F, Amend WJ, Melzer J, Garovoy MR, Roberts JP. Cytokine and T cell receptor gene expression at the site of allograft rejection. Transplantation. 1992 Jan; 53(1):151-6. View in PubMed
  202. Vincenti F, Weber P, Kuo G, Forsell J, Hunt S, Melzer J, Salvatierra O, Stempel C. Hepatitis C virus in cadaver organ donors: prevalence and risk of transmission to transplant recipients. Transplant Proc. 1991 Oct; 23(5):2651-2. View in PubMed
  203. Salvatierra O, McVicar J, Melzer J, Amend W, Vincenti F, Tomlanovich S, Husing R, Rabkin J, Garovoy M. Improved results with combined donor-specific transfusion (DST) and sequential therapy protocol. Transplant Proc. 1991 Feb; 23(1 Pt 2):1024-6. View in PubMed
  204. Stempel C, Lake J, Ferrell L, Tomlanovich S, Amend W, Salvatierra O, Vincenti F. Effect of cyclosporine on the clinical course of HBsAg-positive renal transplant patients. Transplant Proc. 1991 Feb; 23(1 Pt 2):1251-2. View in PubMed
  205. Vincenti F, Biava C, Tomlanovitch S, Amend WJ, Garovoy M, Melzer J, Feduska N, Salvatierra O. Inability of cyclosporine to completely prevent the recurrence of focal glomerulosclerosis after kidney transplantation. Transplantation. 1989 Apr; 47(4):595-8. View in PubMed
  206. Lockard-Marduel A, Gumbert M, Tomlanovich S, Amend W, Vincenti F, Schralla P, Melzer J, Feduska NJ, Salvatierra O, Garovoy MR. Immunologic alterations induced by donor-specific transfusion. Transplant Proc. 1989 Feb; 21(1 Pt 1):1171-2. View in PubMed
  207. Melzer JS, Husing R, Lou C, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Salvatierra O. Successful management of the highly sensitized renal allograft recipient. Transplant Proc. 1989 Feb; 21(1 Pt 1):751-3. View in PubMed
  208. Tomlanovich SJ, Sabatte-Caspillo J, Melzer J, Amend W, Vincenti F, Feduska N, Salvatierra O. The incidence and impact of herpes simplex virus infections in the first month following renal transplantation. Transplant Proc. 1989 Feb; 21(1 Pt 2):2091-2. View in PubMed
  209. Feduska NJ, Melzer JS, Amend WJ, Vincenti F, Tomlanovich SJ, Garovoy M, Husing R, Salvatierra O. Cyclosporine provides better success rates for both higher- and lower-risk cadaveric kidney transplant recipients. Transplant Proc. 1988 Jun; 20(3 Suppl 3):102-9. View in PubMed
  210. Melzer JS, Husing RM, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Lou C, Salvatierra O. How to improve results for second renal allografts. Transplant Proc. 1988 Jun; 20(3 Suppl 3):176-9. View in PubMed
  211. Tomlanovich S, Vincenti F, Amend W, Biava C, Melzer J, Feduska N, Salvatierra O. Is cyclosporine effective in preventing recurrence of immune-mediated glomerular disease after renal transplantation? Transplant Proc. 1988 Jun; 20(3 Suppl 4):285-8. View in PubMed
  212. Hricak H, Terrier F, Marotti M, Engelstad BL, Filly RA, Vincenti F, Duca RM, Bretan PN, Higgins CB, Feduska N. Posttransplant renal rejection: comparison of quantitative scintigraphy, US, and MR imaging. Radiology. 1987 Mar; 162(3):685-8. View in PubMed
  213. Salvatierra O, Melzer J, Vincenti F, Amend WJ, Tomlanovich S, Potter D, Husing R, Garovoy M, Feduska NJ. Donor-specific blood transfusions versus cyclosporine--the DST story. Transplant Proc. 1987 Feb; 19(1 Pt 1):160-6. View in PubMed
  214. Melzer JS, Husing RM, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Salvatierra O. Has cyclosporine really relegated pretransplant blood transfusions to therapeutic obsolescence? Transplant Proc. 1987 Feb; 19(1 Pt 3):1971-3. View in PubMed
  215. Feduska NJ, Perkins HA, Melzer J, Amend WJ, Vincenti F, Tomlanovich S, Garovoy M, Salvatierra O. Observations relating to the incidence of the acquired immune deficiency syndrome and other possibly associated conditions in a large population of renal transplant recipients. Transplant Proc. 1987 Feb; 19(1 Pt 3):2161-6. View in PubMed
  216. Linkowski GD, Warvariv V, Filly RA, Vincenti F. Sonography in the diagnosis of acute renal allograft rejection and cyclosporine nephrotoxicity. AJR Am J Roentgenol. 1987 Feb; 148(2):291-5. View in PubMed
  217. Melzer JS, Husing RM, Feduska NJ, Tomlanovich SJ, Vincenti F, Amend WJ, Garovoy M, Salvatierra O. The beneficial effect of pretransplant blood transfusions in cyclosporine-treated cadaver renal allograft recipients. Transplantation. 1987 Jan; 43(1):61-4. View in PubMed
  218. Hoddick W, Filly RA, Backman U, Callen PW, Vincenti F, Hricak H, Mahony BS, Amend W. Renal allograft rejection: US evaluation. Radiology. 1986 Nov; 161(2):469-73. View in PubMed
  219. Bachman U, Biava C, Amend W, Feduska N, Melzer J, Salvatierra O, Vincenti F. The clinical course of IgA-nephropathy and Henoch-Schönlein purpura following renal transplantation. Transplantation. 1986 Nov; 42(5):511-5. View in PubMed
  220. Feduska NJ, Melzer J, Amend WJ, Vincenti F, Tomlanovich S, Salvatierra O. Clinical management of immunosuppressive therapy for cyclosporine-treated recipients of cadaver kidney transplants at one to six months. Transplant Proc. 1986 Apr; 18(2 Suppl 1):136-40. View in PubMed
  221. Stabile C, Vincenti F, Garovoy M, Duca R, Melzer J, Feduska NJ, Salvatierra O, Amend WJ. Is a "low" dose of prednisone better than a "high" dose at the time of renal transplantation? Braz J Med Biol Res. 1986; 19(3):355-66. View in PubMed
  222. Salvatierra O, Melzer J, Potter D, Garovoy M, Vincenti F, Amend WJ, Husing R, Hopper S, Feduska NJ. A seven-year experience with donor-specific blood transfusions. Results and considerations for maximum efficacy. Transplantation. 1985 Dec; 40(6):654-9. View in PubMed
  223. Shermantine M, Gambertoglio J, Amend W, Vincenti F, Oie S. Pharmacokinetics of sulfisoxazole in renal transplant patients. Antimicrob Agents Chemother. 1985 Oct; 28(4):535-9. View in PubMed
  224. Feduska NJ, Melzer J, Amend W, Vincenti F, Duca R, Garovoy M, Hopper S, Salvatierra O. Dramatic improvement in the success rate for renal transplants in diabetic recipients with donor-specific transfusions. Transplantation. 1984 Dec; 38(6):704-8. View in PubMed
  225. Feduska NJ, Amend WJ, Vincenti F, Melzer JS, Duca R, Garovoy MR, Salvatierra O. Peptic ulcer disease in kidney transplant recipients. Am J Surg. 1984 Jul; 148(1):51-7. View in PubMed
  226. Vincenti F, Arnaud SB, Recker R, Genant H, Amend WJ, Feduska NJ, Salvatierra O. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int. 1984 Apr; 25(4):677-82. View in PubMed
  227. Vincenti F, Amend WJ, Kaysen G, Feduska N, Birnbaum J, Duca R, Salvatierra O. Long-term renal function in kidney donors. Sustained compensatory hyperfiltration with no adverse effects. Transplantation. 1983 Dec; 36(6):626-9. View in PubMed
  228. Salvatierra O, Vincenti F, Amend WJ, Garovoy MR, Potter D, Feduska NJ. The role of blood transfusions in renal transplantation. Urol Clin North Am. 1983 May; 10(2):243-52. View in PubMed
  229. Berger BE, Vincenti F, Biava C, Amend WJ, Feduska N, Salvatierra O. De novo and recurrent membranous glomerulopathy following kidney transplantation. Transplantation. 1983 Apr; 35(4):315-9. View in PubMed
  230. Benet LZ, Smith DE, Lin ET, Vincenti F, Gambertoglio JG. Furosemide assays and disposition in healthy volunteers and renal transplant patients. Fed Proc. 1983 Apr; 42(6):1695-8. View in PubMed
  231. O'Connor DT, Barg AP, Amend W, Vincenti F. Urinary kallikrein excretion after renal transplantation: relationship to hypertension, graft source, and renal function. Am J Med. 1982 Oct; 73(4):475-81. View in PubMed
  232. Feduska NJ, Amend WJ, Vincenti F, Duca R, Salvatierra O. Blood transfusions before and on the day of transplantation: effects on cadaver graft survival. Transplant Proc. 1982 Jun; 14(2):302-4. View in PubMed
  233. Salvatierra O, Iwaki Y, Vincenti F, Amend W, Terasaki P, Garovoy M, Duca R, Hopper S, Feduska N. Update of the University of California at San Francisco experience with donor-specific blood transfusions. Transplant Proc. 1982 Jun; 14(2):363-6. View in PubMed
  234. Vincenti F, Amend WJ, Feduska NJ, Salvatierra O. Blood transfusions and kidney transplantation. Arch Intern Med. 1982 Apr; 142(4):680-1. View in PubMed
  235. Gambertoglio JG, Frey FJ, Holford NH, Birnbaum JL, Lizak PS, Vincenti F, Feduska NJ, Salvatierra O, Amend WJ. Prednisone and prednisolone bioavailability in renal transplant patients. Kidney Int. 1982 Apr; 21(4):621-6. View in PubMed
  236. Amend WJ, Vincenti F, Duca R, Feduska NJ, Cochrum K, Potter D, Salvatierra O. Prognostic features of early renal transplant rejections. Am J Kidney Dis. 1982 Mar; 1(5):281-7. View in PubMed
  237. Vincenti F, Amend WJ, Feduska NJ, Salvatierra O. Septic arthritis following renal transplantation. Nephron. 1982; 30(3):253-6. View in PubMed
  238. Feduska NJ, Vincenti F, Amend W, Iwaki Y, Opelz G, Terasaki P, Duca R, Hopper S, Salvatierra O. An alternative to cadaver kidney transplants for patients with insulin-dependent diabetes mellitus. Transplantation. 1981 Dec; 32(6):517-21. View in PubMed
  239. Salvatierra O, Iwaki Y, Vincenti F, Amend W, Potter D, Opelz G, Terasaki P, Duca R, Hopper S, Feduska N. Incidence, characteristics, and outcome of recipients sensitized after donor-specific blood transfusions. Transplantation. 1981 Dec; 32(6):528-31. View in PubMed
  240. Cochrum K, Hanes D, Potter D, Perkins H, Amend W, Vincenti F, Iwaki Y, Opelz G, Terasaki P, Levin B, Sampson D, Feduska N, Salvatierra O. Improved graft survival following donor-specific blood transfusions. Transplant Proc. 1981 Sep; 13(3):1657-61. View in PubMed
  241. Cogan MG, Sargent JA, Yarbrough SG, Vincenti F, Amend WJ. Prevention of prednisone-induced negative nitrogen balance. Effect of dietary modification on urea generation rate in patients on hemodialysis receiving high-dose glucocorticoids. Ann Intern Med. 1981 Aug; 95(2):158-61. View in PubMed
  242. Salvatierra O, Amend W, Vincenti F, Potter D, Stoney R, Duca R, Feduska N. 1,500 renal transplants at one center: evolution of a strategy for optimal success. Am J Surg. 1981 Jul; 142(1):14-20. View in PubMed
  243. Smith DE, Gambertoglio JG, Vincenti F, Benet LZ. Furosemide kinetics and dynamics after kidney transplant. Clin Pharmacol Ther. 1981 Jul; 30(1):105-13. View in PubMed
  244. Amend WJ, Vincenti F, Feduska NJ, Salvatierra O, Johnston WH, Jackson J, Tilney N, Garovoy M, Burwell EL. Recurrent systemic lupus erythematosus involving renal allografts. Ann Intern Med. 1981 Apr; 94(4 pt 1):444-8. View in PubMed
  245. Vincenti F, Hattner R, Amend WJ, Feduska NJ, Duca RM, Salvatierra O. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. JAMA. 1981 Mar 06; 245(9):930-3. View in PubMed
  246. Feduska NJ, Amend WJ, Vincenti F, Perkins HA, Opelz G, Terasaki PI, Iwaki Y, Duca R, Dodge D, Salvatierra O. Graft survival with high levels of cytotoxic antibodies. Transplant Proc. 1981 Mar; 13(1 Pt 1):73-80. View in PubMed
  247. Cochrum K, Hanes D, Potter D, Perkins H, Amend W, Vincenti F, Iwaki Y, Opelz G, Terasaki P, Feduska N, Salvatierra O. Improved graft survival with donor-specific transfusion pretreatment. Transplant Proc. 1981 Mar; 13(1 Pt 1):190-3. View in PubMed
  248. Salvatierra O, Amend W, Vincenti F, Potter D, Iwaki Y, Opelz G, Terasaki P, Duca R, Hanes D, Cochrum KC, Hopper S, Feduska NJ. Pretreatment with donor-specific blood transfusions in related recipients with high MLC. Transplant Proc. 1981 Mar; 13(1 Pt 1):142-9. View in PubMed
  249. Gambertoglio JG, Vincenti F, Feduska NJ, Birnbaum J, Salvatierra O, Amend WJ. Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. J Clin Endocrinol Metab. 1980 Sep; 51(3):561-5. View in PubMed
  250. Vincenti F, Amend W, Feduska NJ, Duca RM, Salvatierra O. Improved outcome following renal transplantation with reduction in the immunosuppression therapy for rejection episodes. Am J Med. 1980 Jul; 69(1):107-12. View in PubMed
  251. Vincenti F, Amend WJ, Abele J, Feduska NJ, Salvatierra O. The role of hypertension in hemodialysis-associated atherosclerosis. Am J Med. 1980 Mar; 68(3):363-9. View in PubMed
  252. Pearson JC, Amend WJ, Vincenti FG, Feduska NJ, Salvatierra O. Post-transplantation pyelonephritis: factors producing low patient and transplant morbidity. J Urol. 1980 Feb; 123(2):153-6. View in PubMed
  253. Salvatierra O, Vincenti F, Amend W, Potter D, Iwaki Y, Opelz G, Terasaki P, Duca R, Cochrum K, Hanes D, Stoney RJ, Feduska NJ. Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg. 1980; 192(4):543-52. View in PubMed
  254. Hopper S, Feduska N, Vincenti F, Amend W, Salvatierra O. The organization of a successful donor-specific transfusion protocol in related recipients with high MLC. Proc Clin Dial Transplant Forum. 1980; 10:272-6. View in PubMed
  255. Cochrum KC, Hanes D, Potter D, Vincenti F, Amend W, Feduska N, Perkins H, Salvatierra O. Donor-specific blood transfusions in HLA-D-disparate one-haplotype-related allografts. Transplant Proc. 1979 Dec; 11(4):1903-7. View in PubMed
  256. Spring DB, Salvatierra O, Palubinskas AJ, Amend WJ, Vincenti FG, Feduska NJ. Results and significance of angiography in potential kidney donors. Radiology. 1979 Oct; 133(1):45-7. View in PubMed
  257. Wolf JL, Perkins HA, Schreeder MT, Vincenti F. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med. 1979 Sep; 91(3):412-3. View in PubMed
  258. Salvatierra O, Feduska NJ, Vincenti F, Duca R, Potter D, Nolan J, Cochrum KC, Amend WJ. Analysis of costs and outcomes of renal transplantation at one center. Its implications. JAMA. 1979 Apr 06; 241(14):1469-73. View in PubMed
  259. Feduska NJ, Collins GM, Amend WJ, Vincenti F, Duca RM, Stieper KW, Mitchell JW, Cochrum KC, Salvatierra O. Comparative study of albumin solution and cryoprecipitated plasma for renal preservation: a preliminary report. Transplant Proc. 1979 Mar; 11(1):472-7. View in PubMed
  260. Cochrum K, Hanes D, Van Speybroeck J, Perkins H, Ferrone S, Indeveri F, Amend W, Vincenti F, Feduska N, Salvatierra O. HLA-D antigen disparity and HLA-DRw antibodies in intrafamilial renal allograft survival. Transplant Proc. 1979 Mar; 11(1):404-10. View in PubMed
  261. Speybroeck JV, Feduska N, Amend W, Vincenti F, Cochrum K, Salvatierra O. The influence of donor age on graft survival. Am J Surg. 1979 Mar; 137(3):374-7. View in PubMed
  262. Feduska NJ, Vincenti F, Amend WJ, Duca R, Cochrum K, Salvatierra O. Do blood transfusions enhance the possibility of a compatible transplant? Transplantation. 1979 Jan; 27(1):35-8. View in PubMed
  263. Vincenti F, Amend W, Feduska N, Duca R, Salvatierra O. Pretransplant cytotoxic antibodies do not segregate kidney transplant recipients into responder and non-responder groups. Proc Eur Dial Transplant Assoc. 1979; 16:419-25. View in PubMed
  264. Vincenti F, Duca RM, Amend W, Perkins HA, Cochrum KC, Feduska NJ, Salvatierra O. Immunologic factors determining survival of cadaver-kidney transplants. The effect of HLA serotyping, cytotoxic antibodies and blood transfusions on graft survival. N Engl J Med. 1978 Oct 12; 299(15):793-8. View in PubMed
  265. Cochrum KC, Haynes DM, Salvatierra O, Feduska NJ, Vincenti F, Van Speybroeck J. Leukocyte migration inhibitory factor (LIF) as an indicator of presensitization and allograft survival. Transplant Proc. 1978 Jun; 10(2):455-8. View in PubMed
  266. Feduska NJ, Belzer FO, Stieper KW, Duca RM, Mitchell JW, Vincenti F, Cochrum KC, Salvatierra O. A ten year experience with cadaver kidney preservation using cryoprecipitated plasma. Am J Surg. 1978 Mar; 135(3):356-61. View in PubMed
  267. Feduska NJ, Amend WJ, Vincenti F, Duca RM, Stieper KW, Mitchell JW, Cochrum KC, Salvatierra O. Cadaver kidney transplantation provided from one center within a large geographical region. Trans Am Soc Artif Intern Organs. 1978; 24:270-7. View in PubMed
  268. Vincenti F, Amend W, Feduska N, Maglio M, Axel L, Cochrum K, Salvatierra O. The effect of hypothermic pulsatile perfusion on glomerular epithelial surface structures studied by scanning electron microscopy. Trans Am Soc Artif Intern Organs. 1978; 24:257-60. View in PubMed
  269. Denes AE, Berquist KR, Fields HA, Vincenti F. Hepatitis-B reactivation after renal transplantation. Lancet. 1977 Jun 18; 1(8025):1314. View in PubMed
  270. Vincenti FG, Heymsfield S. Reversible malignant hypertension and azotemia due to urethral stricture. Arch Intern Med. 1977 Mar; 137(3):370-2. View in PubMed
  271. Amend W, Vincenti F, Covey C, Epstein W, Feduska N, Salvatierra O. Renal transplantation in systemic lupus erythematosus. Proc Clin Dial Transplant Forum. 1977; 7:18-22. View in PubMed
  272. Hajjar ET, Vincenti F, Salti IS. Gluten-induced enteropathy. Osteomalacia as its principal manifestation. Arch Intern Med. 1974 Sep; 134(3):565-6. View in PubMed
  273. Vincenti F, Birbari A, Rizk G. Renal vein renin in hypertension. Diagnostic and therapeutic implications. J Med Liban. 1973; 26(1):9-16. View in PubMed
  274. Vincenti F, Hajjar ET, Salti IS. Tumorous hyperparathyroidism in hypophosphatemic vitamin D--resistant rickets. J Med Liban. 1973; 26(6):583-94. View in PubMed